Monotherapy for low-risk gestational trophoblastic neoplasia with score 5-6

Li Kemin; Li Kemin; Zhang Mengpei; Zhang Mengpei; Yin Rutie; Yin Rutie

doi:10.3389/fonc.2022.1035170

Frontiers in Oncology (Nov 2022)

Monotherapy for low-risk gestational trophoblastic neoplasia with score 5-6

Li Kemin,
Li Kemin,
Zhang Mengpei,
Zhang Mengpei,
Yin Rutie,
Yin Rutie

Affiliations

Li Kemin: The Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China
Li Kemin: Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, Sichuan, China
Zhang Mengpei: The Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China
Zhang Mengpei: Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, Sichuan, China
Yin Rutie: The Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, Sichuan, China
Yin Rutie: Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, Sichuan, China

DOI: https://doi.org/10.3389/fonc.2022.1035170
Journal volume & issue: Vol. 12

Abstract

Read online

ObjectiveTo investigate the monotherapy for gestational trophoblastic neoplasia (GTN) patients with FIGO/WHO prognostic score of 5–6.MethodsThe low-risk GTN patients from 2012 to 2019 were enrolled. The study is a retrospective report to analyze the efficacy and safety of single-agent chemotherapy and combination chemotherapy in patients with a high FIGO/WHO prognostic score of 5–6.Results75 cases (33.5%) were included. Complete remission was in all patients. Among the 29 cases taking single-agent chemotherapy, 22 cases (75.9%) developed drug resistance. Among the 46 cases taking combination chemotherapy, 7 patients (15.2%) developed drug resistance. There was a statistically significant difference in the drug resistance rate between these two subgroups (P < 0.05), but there was not statistically significant difference in the total number of chemotherapy courses (<2mIU/ml) (P < 0.05).ConclusionMonotherapy showed remarkable advantages in GTN patients with FIGO/WHO prognostic score of 5–6.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords